{"entity":{"id":"fbxo11","kind":"target","name":"FBXO11","aka":["F-box protein 11","F-box only protein 11","FBX11","UBR6"],"tldr":"FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","summary":"Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1. The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal centre B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signalling, cell migration and the timing of the cell-cycle progression and exit.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes literature 0.96, animal model 0.49, genetic association 0.87, somatic mutation 0.97). IntOGen calls it a driver in 5 cohorts (1 activating, 4 loss-of-function), covering Burkitt Lymphoma, Malignant Lymphoma, Non-Hodgkin Lymphoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:13590","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13590"},{"label":"UniProt Q86XK2","url":"https://www.uniprot.org/uniprotkb/Q86XK2/entry"},{"label":"NCBI Gene 80204","url":"https://www.ncbi.nlm.nih.gov/gene/80204"},{"label":"Ensembl ENSG00000138081","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138081"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["colorectal","endometrial","ovarian","breast-cancer","gastric","non-hodgkin-lymphoma","prostate","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FBXO11","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:13590","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13590","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q86XK2","url":"https://www.uniprot.org/uniprotkb/Q86XK2/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FBXO11","url":"https://civicdb.org/features/15318","note":"1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000138081","url":"https://platform.opentargets.org/target/ENSG00000138081/associations","note":"association with cancer (MONDO_0004992) 0.83; per-cancer scores at or above 0.5: colorectal cancer 0.79, gastric cancer 0.65, prostate cancer 0.60, ovarian cancer 0.72, endometrial cancer 0.74, melanoma 0.52 (GraphQL API, CC0)"},{"label":"IntOGen FBXO11","url":"https://www.intogen.org/search?gene=FBXO11","note":"driver in 5 cohorts (Act 1, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"many-types","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FBXO11: RNA low tissue specificity; no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Endometrial cancer, Ovarian cancer, Breast cancer (all types), Gastric & gastro-oesophageal junction cancer, Lymphoma, Prostate cancer and more); Open Targets associates it with 15 specific cancer types at or above 0.5 (Lynch syndrome, endometrial carcinoma, colon carcinoma, ovarian cancer, hereditary neoplastic syndrome, hereditary nonpolyposis colon cancer and more). (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q86XK2","url":"https://www.uniprot.org/uniprotkb/Q86XK2/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FBXO11","url":"https://civicdb.org/features/15318","note":"1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen FBXO11","url":"https://www.intogen.org/search?gene=FBXO11","note":"driver in 5 cohorts (Act 1, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas FBXO11 tissue","url":"https://www.proteinatlas.org/ENSG00000138081-FBXO11/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000138081 associations","url":"https://platform.opentargets.org/target/ENSG00000138081/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:13590","ensembl":"ENSG00000138081","uniprot":"Q86XK2","entrez":"80204","firstDescribed":1999,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Cenciarelli et al, Curr. Biol, 1999, \"Identification of a family of human F-box proteins\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/10531035/","biology":"Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1. The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal centre B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signalling, cell migration and the timing of the cell-cycle progression and exit. The SCF(FBXO11) complex also catalyses ubiquitination and degradation of GSK3B-phosphorylated SNAI1. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. Plays a role in the regulatiom of erythropoiesis but not myelopoiesis or megakaryopoiesis. Location: Nucleus; Chromosome (UniProt). Locus 2p16.3 (HGNC).","whereFound":["Colorectal cancer: Open Targets association 0.79 with colorectal cancer (MONDO_0005575)","Endometrial cancer: Open Targets association 0.74 with endometrial cancer (MONDO_0011962)","Ovarian cancer: Open Targets association 0.72 with ovarian cancer (MONDO_0008170)","Breast cancer: Open Targets association 0.69 with breast cancer (MONDO_0007254)","Gastric & gastro-oesophageal junction cancer: Open Targets association 0.65 with gastric cancer (MONDO_0001056)","Non-Hodgkin lymphoma: Open Targets association 0.62 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 3 cohorts (MLYM, NHL)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/fbxo11/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}]}}